New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
06:34 EDTJAZZJazz Pharmaceuticals trades at attractive risk/reward, says Piper Jaffray
Piper Jaffray believes Jazz Pharmaceuticals' acquisition of the U.S. rights to Defitelio makes the company's long-term growth story even more attractive. Piper says Jazz shares trade at an attractive risk/reward and it reiterates an Overweight rating on the name with a $200 price target.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
08:12 EDTJAZZJazz Pharmaceuticals management to meet with Leerink
Subscribe for More Information
07:21 EDTJAZZUBS to hold a conference
Subscribe for More Information
May 18, 2015
12:24 EDTJAZZJazz Pharmaceuticals management to meet with Guggenheim
Subscribe for More Information
May 8, 2015
11:39 EDTJAZZFlamel jumps after competitors scrap narcolepsy drug development
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use